Glucagon News and Research

RSS

Could chlorophyll become the next antidiabetic therapy?

Research highlights chlorophyll's role in blood sugar regulation and insulin mimicry, though safety risks and lack of human trials warrant caution.

20 Aug 2025

Towards fully automated artificial pancreas systems for better diabetes care

Automated insulin delivery (AID) systems such as the UVA Health-developed artificial pancreas could help more type 1 diabetes patients if the devices become fully automated, according to a new review of the technology.

19 Aug 2025

GIPR signaling opens brain’s gate for GLP-1 weight-loss therapy

A Cell Metabolism study reveals that GIPR signaling in oligodendrocytes enhances brain access and weight-loss efficacy of GLP-1R agonists by increasing vascular permeability and targeting appetite-regulating neurons. This mechanism may explain why GIPR/GLP-1R co-agonists outperform single-agent therapies.

14 Aug 2025

Diabetes drugs linked to higher risk of rare optic nerve damage

...

14 Aug 2025

Research shows GLP-1 drugs safeguard vision despite small retinopathy risk

A large study of over 185,000 adults with type 2 diabetes found that GLP-1 receptor agonist use was linked to a slight increase in new diabetic retinopathy cases but fewer severe eye complications, including a reduced risk of blindness. Patients with existing retinopathy on these drugs also needed fewer invasive eye treatments over two years.

13 Aug 2025

Study supports pre-surgery use of GLP-1 RAs for weight reduction

Overweight patients waiting for operations could safely use a particular type of weight-loss treatment to reduce the risk of surgical complications linked to their obesity, a new study reveals.

12 Aug 2025

Brain’s energy control map offers blueprint for next-gen weight loss therapies

Scientists map how the brain integrates hormonal and neural signals from the body to control appetite, energy use, and reward pathways, revealing targets for next-generation anti-obesity drugs. This review highlights the interplay between neuroendocrine circuits, neuroplasticity, and pharmacotherapy for durable, non-aversive weight loss.

11 Aug 2025

HIV trial points to semaglutide as a new anti-aging contender

Once-weekly semaglutide significantly slowed epigenetic aging in adults with HIV-associated lipohypertrophy, as measured by multiple DNA methylation clocks in a randomized controlled trial. These exploratory findings suggest GLP-1 receptor agonists could impact biological aging but require further validation in broader populations.

4 Aug 2025

Metformin’s blood sugar control starts in the brain, not just the liver, study finds

Low, clinically relevant doses of metformin lower blood glucose by inhibiting the Rap1 protein in specific neurons of the hypothalamus, revealing a brain-first mechanism. This action is essential for metformin’s effect at therapeutic doses and highlights new directions for diabetes treatment.

3 Aug 2025

Gut microbial metabolites restore hormone-producing cells in obesity

New research from scientists at the Marshall University Joan C. Edwards School of Medicine reveals that certain gut microbial byproducts may hold promise as a novel therapy for obesity-associated metabolic complications by restoring critical hormone-producing cells in the intestine.

29 Jul 2025

Which GLP-1 meds have the most side effects? Study of 60,000 Facebook posts gives answers

Researchers analyzed nearly 60,000 public Facebook posts to identify real-world adverse events linked to GLP-1 receptor agonist (GLP-1 RA) medications. Gastrointestinal symptoms were most common, while mental health concerns and tirzepatide-specific side effects were also flagged.

28 Jul 2025

What happens to your weight after quitting GLP-1 anti-obesity drugs?

Stopping anti-obesity medications leads to significant weight regain, starting as early as eight weeks and stabilizing by six months. Despite this rebound, most patients maintain some weight loss compared to baseline a year after discontinuation.

23 Jul 2025

Can one drug do it all? Reviewing the expanding clinical universe of GLP-1 agonists

Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide significant benefits for cardiovascular, kidney, liver, joint, and sleep-related diseases. These effects extend beyond weight loss, suggesting anti-inflammatory mechanisms with broad potential for managing chronic diseases.

22 Jul 2025

Weight regain observed in patients after ending obesity drug treatment

Patients prescribed drugs to help them lose weight may experience a rebound in weight gain after halting their prescription, finds a meta-analysis published in BMC Medicine.

22 Jul 2025

Gut-brain axis in eating disorders offers new treatment potential

Understanding the gut-brain axis is key to addressing eating disorders. This study highlights microbiota's influence and emerging therapeutic approaches.

16 Jul 2025

Tirzepatide reduces obesity-associated breast cancer growth in mouse model

The anti-obesity medication tirzepatide, marketed as Mounjaro for diabetes and Zepbound for obesity, reduced obesity-associated breast cancer growth in a mouse model, according to a study being presented Saturday at ENDO 2025, the Endocrine Society's annual meeting in San Francisco, Calif.

12 Jul 2025

MIT develops implantable device to automatically release emergency glucagon

For people with Type 1 diabetes, developing hypoglycemia, or low blood sugar, is an ever-present threat. When glucose levels become extremely low, it creates a life-threatening situation for which the standard treatment of care is injecting a hormone called glucagon.

9 Jul 2025

Innovative genome editing approach could be the key to lifelong effective weight management

Weight-loss drugs have surged in popularity, promising rapid results with regular injections. Now, researchers from Japan report a way for the body to make its own weight-loss drugs, doing away with injections in favor of a one-time treatment.

9 Jul 2025

New study identifies factors linked to successful weight loss using GLP-1RAs

A study in Diabetes, Obesity and Metabolism has identified certain characteristics that might influence people's weight loss after taking prescription drugs called glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as semaglutide (sold under the brand names Ozempic and Wegovy).

9 Jul 2025

Tirzepatide tops the charts for blood sugar and weight loss in type 2 diabetes

A large network meta-analysis ranked eight GLP-1 receptor agonists for glycemic, weight, and safety outcomes in adults with type 2 diabetes. Tirzepatide demonstrated the greatest efficacy for glucose control and weight loss, while liraglutide offered the lowest hypoglycemia risk.

7 Jul 2025